trimethyloxamine has been researched along with Apoplexy in 35 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although trimethylamine-N-oxide (TMAO) shows a notable correlation with cardiovascular disease, its association with acute ischemic stroke (AIS) remains uncertain and necessitates further investigation." | 9.41 | The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis. ( Duan, Y; Guo, Z; Hong, Y; Li, Y; Liu, N; Sun, Z; Xu, Q; Yang, K, 2023) |
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 9.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 8.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Although trimethylamine-N-oxide (TMAO) shows a notable correlation with cardiovascular disease, its association with acute ischemic stroke (AIS) remains uncertain and necessitates further investigation." | 5.41 | The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis. ( Duan, Y; Guo, Z; Hong, Y; Li, Y; Liu, N; Sun, Z; Xu, Q; Yang, K, 2023) |
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 5.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| "Increased TMAO was associated with higher stroke risk in the community-based population, whereas the TMAO precursors carnitine, choline, betaine, and TML were not associated." | 4.31 | Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study. ( Gu, S; Liu, D; Ma, Z; Zhou, Z; Zuo, H, 2023) |
| "There is increasing evidence for the association of trimethylamine-N-oxide (TMAO) with cognitive impairment after minor stroke or transient ischemic attack (TIA)." | 4.31 | Association between plasma trimethylamine-N-oxide and cognitive impairment in patients with transient ischemic attack. ( Bao, Y; Huang, D; Jiang, L; Qv, S; Wang, J; Wang, L; Xu, G; Yang, J; Zhan, X, 2023) |
| " We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual-antiplatelet therapy and intensive lipid-lowering therapy and with a low inflammation level (high-sensitivity C-reactive protein <2 mg/L on admission)." | 4.12 | Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy. ( Cheng, A; Jiang, X; Jin, A; Li, H; Li, K; Lin, J; Meng, X; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| "Increased levels of lactic acid, pyruvate, and TMAO may be related to the pathophysiological changes in the minor ischaemic stroke population." | 4.12 | Related factors based on non-targeted metabolomics methods in minor ischaemic stroke. ( Chen, C; Ding, L; Guo, J; Liu, H; Ma, Y; Qiao, X; Wang, J; Wang, M; Yang, T; Zhao, S, 2022) |
| "A total of 64 patients with acute ischemic stroke were randomized into an observation group and a control group, 32 cases in each one." | 3.11 | [ ( Du, XZ; Lei, SQ; Liu, MK; Wang, H; Yuan, B, 2022) |
| "As we know, ischemic stroke is a heterogeneous disease with variable pathogenesis." | 2.82 | Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes. ( Cheng, A; Dai, L; Jing, J; Li, H; Meng, X; Song, B; Wang, A; Wang, Y; Xu, J; Xue, J; Zhao, M; Zheng, L, 2022) |
| " This study aimed to review the available scientific evidence about the relationship between TMAO levels and the risk of stroke in a dose-response meta-analysis." | 2.82 | Plasmatic trimethylamine N-oxide and its relation to stroke: A systematic review and dose-response meta-analysis. ( Chen, P; Guo, Z, 2022) |
| " Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7." | 2.55 | Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. ( Esposito, G; Franzone, A; Gargiulo, G; Giugliano, G; Perrino, C; Sannino, A; Schiattarella, GG; Toscano, E; Trimarco, B, 2017) |
| "Stroke is the second most common cause of cognitive impairment and dementia." | 1.91 | Exploratory Transcriptomic Profiling Reveals the Role of Gut Microbiota in Vascular Dementia. ( Buffa, J; Kaur, N; LaForce, G; Li, XS; Mallela, DP; Rothenberg, K; Saha, PP; Sangwan, N; Zhu, W, 2023) |
| " Trimethylamine N-oxide level, Acute ischemic stroke, Early neurological deterioration, NIHSS score." | 1.91 | Utility of Trimethylamine Oxide (TMAO) in Predicting Early Neurological Deterioration after Acute Ischemic Stroke. ( Cheng, H; Kang, Y; Liu, J; Shi, Y; Wan, D; Wang, Y, 2023) |
| "TMAO was associated with lacunar stroke but not other ischemic stroke subtypes in a model adjusted for age, sex, hypertension, diabetes, and smoking (OR, 1." | 1.91 | Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke. ( Ament, Z; Bevers, MB; Bhave, VM; Couch, CA; Garcia Guarniz, AL; Irvin, MR; Kijpaisalratana, N; Kimberly, WT, 2023) |
| "In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors." | 1.51 | Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. ( Ahluwalia, TS; Hansen, TW; Hazen, SL; Jorsal, A; Parving, HH; Pedersen, O; Rossing, P; Tarnow, L; Theilade, S; Tofte, N; Wang, Z; Winther, SA; Øllgaard, JC, 2019) |
| "This dysbiosis was correlated with the severity of the disease." | 1.42 | Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. ( Chen, Q; He, Y; Liao, SX; Liu, FT; Pan, SY; Wang, S; Xia, GH; Yin, J; You, C; Zhou, HW; Zhou, L; Zhu, JJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 22 (62.86) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 2 |
| Cheng, A | 2 |
| Song, B | 1 |
| Zhao, M | 2 |
| Xue, J | 2 |
| Wang, A | 2 |
| Dai, L | 1 |
| Jing, J | 1 |
| Meng, X | 2 |
| Li, H | 4 |
| Zheng, L | 2 |
| Wang, Y | 5 |
| Zhang, H | 2 |
| Yao, G | 1 |
| Chen, P | 1 |
| Guo, Z | 2 |
| Wang, H | 2 |
| Lei, SQ | 1 |
| Du, XZ | 1 |
| Yuan, B | 1 |
| Liu, MK | 1 |
| Jin, A | 1 |
| Jiang, X | 2 |
| Li, K | 1 |
| Lin, J | 1 |
| Liu, D | 1 |
| Gu, S | 1 |
| Zhou, Z | 2 |
| Ma, Z | 1 |
| Zuo, H | 1 |
| Chen, C | 2 |
| Qiao, X | 1 |
| Guo, J | 1 |
| Yang, T | 1 |
| Wang, M | 1 |
| Ma, Y | 1 |
| Zhao, S | 1 |
| Ding, L | 1 |
| Liu, H | 2 |
| Wang, J | 2 |
| Tu, R | 1 |
| Xia, J | 1 |
| Lemaitre, RN | 2 |
| Jensen, PN | 2 |
| Mozaffarian, D | 2 |
| Wang, L | 2 |
| Zhan, X | 1 |
| Jiang, L | 1 |
| Xu, G | 1 |
| Bao, Y | 1 |
| Qv, S | 1 |
| Yang, J | 1 |
| Huang, D | 1 |
| Kaur, N | 1 |
| LaForce, G | 1 |
| Mallela, DP | 1 |
| Saha, PP | 1 |
| Buffa, J | 1 |
| Li, XS | 5 |
| Sangwan, N | 2 |
| Rothenberg, K | 1 |
| Zhu, W | 4 |
| Chou, PS | 1 |
| Yang, IH | 1 |
| Kuo, CM | 1 |
| Wu, MN | 1 |
| Lin, TC | 1 |
| Fong, YO | 1 |
| Juan, CH | 1 |
| Lai, CL | 1 |
| Kang, Y | 1 |
| Cheng, H | 1 |
| Shi, Y | 1 |
| Liu, J | 1 |
| Wan, D | 1 |
| Wang, Z | 5 |
| Fretts, AM | 1 |
| Sitlani, CM | 1 |
| Nemet, I | 1 |
| Sotoodehnia, N | 1 |
| de Oliveira Otto, MC | 1 |
| Budoff, M | 1 |
| Longstreth, WT | 1 |
| Psaty, BM | 1 |
| Siscovick, DS | 1 |
| Hazen, SL | 6 |
| Kijpaisalratana, N | 1 |
| Ament, Z | 1 |
| Bevers, MB | 1 |
| Bhave, VM | 1 |
| Garcia Guarniz, AL | 1 |
| Couch, CA | 1 |
| Irvin, MR | 1 |
| Kimberly, WT | 1 |
| Hong, Y | 1 |
| Sun, Z | 1 |
| Liu, N | 1 |
| Yang, K | 1 |
| Li, Y | 2 |
| Xu, Q | 1 |
| Duan, Y | 1 |
| Zhu, C | 1 |
| Li, G | 2 |
| Lv, Z | 1 |
| Li, J | 1 |
| Wang, X | 2 |
| Kang, J | 1 |
| Zhan, C | 1 |
| Gencer, B | 2 |
| Gurmu, Y | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Cohen, M | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Johanson, P | 1 |
| Sabatine, MS | 1 |
| Farhangi, MA | 1 |
| Vajdi, M | 1 |
| Asghari-Jafarabadi, M | 1 |
| Zhong, C | 1 |
| Lu, Z | 1 |
| Che, B | 1 |
| Qian, S | 1 |
| Zheng, X | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| Zhang, Y | 1 |
| Xu, D | 1 |
| Zhao, W | 2 |
| Song, J | 1 |
| Yin, L | 1 |
| Wang, K | 1 |
| Wei, L | 1 |
| Xu, Y | 1 |
| Min, B | 1 |
| Tang, N | 1 |
| Yan, S | 1 |
| Leng, H | 1 |
| Xue, Q | 1 |
| Peng, M | 1 |
| Romano, KA | 1 |
| Li, L | 2 |
| Buffa, JA | 1 |
| Prakash, P | 1 |
| Tittle, AN | 1 |
| Fu, X | 1 |
| Androjna, C | 1 |
| DiDonato, AJ | 1 |
| Brinson, K | 1 |
| Trapp, BD | 1 |
| Fischbach, MA | 1 |
| Rey, FE | 1 |
| Hajjar, AM | 1 |
| DiDonato, JA | 1 |
| Schiattarella, GG | 1 |
| Sannino, A | 1 |
| Toscano, E | 1 |
| Giugliano, G | 1 |
| Gargiulo, G | 1 |
| Franzone, A | 1 |
| Trimarco, B | 1 |
| Esposito, G | 1 |
| Perrino, C | 1 |
| Yu, W | 1 |
| Xu, C | 1 |
| Hong, W | 1 |
| Xiao, C | 1 |
| Zhao, Y | 2 |
| Cai, Y | 2 |
| Huang, M | 1 |
| Jin, J | 1 |
| Wu, C | 1 |
| Li, C | 1 |
| Xie, N | 1 |
| Yan, F | 1 |
| Lian, Y | 1 |
| Zhou, L | 2 |
| Xu, X | 2 |
| Liang, Y | 1 |
| Ren, M | 1 |
| Li, S | 1 |
| Cheng, X | 1 |
| Zhang, L | 1 |
| Ma, Q | 1 |
| Song, H | 1 |
| Meng, R | 1 |
| Ji, X | 1 |
| Haghikia, A | 2 |
| Liman, TG | 1 |
| Bledau, N | 1 |
| Schmidt, D | 1 |
| Zimmermann, F | 1 |
| Kränkel, N | 1 |
| Widera, C | 1 |
| Sonnenschein, K | 1 |
| Weissenborn, K | 1 |
| Fraccarollo, D | 1 |
| Heimesaat, MM | 1 |
| Bauersachs, J | 1 |
| Bavendiek, U | 1 |
| Endres, M | 1 |
| Landmesser, U | 1 |
| Nie, J | 1 |
| Xie, L | 1 |
| Zhao, BX | 1 |
| Qiu, B | 1 |
| Zhu, F | 1 |
| Li, GF | 1 |
| He, M | 1 |
| Wang, B | 1 |
| Liu, S | 2 |
| Guo, H | 1 |
| Huo, Y | 1 |
| Hou, FF | 1 |
| Qin, X | 1 |
| Liang, Z | 1 |
| Dong, Z | 1 |
| Guo, M | 1 |
| Shen, Z | 1 |
| Yin, D | 1 |
| Hu, S | 1 |
| Hai, X | 1 |
| Stubbs, JR | 1 |
| Stedman, MR | 1 |
| Long, J | 1 |
| Franchetti, Y | 1 |
| West, RE | 1 |
| Prokopienko, AJ | 1 |
| Mahnken, JD | 1 |
| Chertow, GM | 1 |
| Nolin, TD | 1 |
| Winther, SA | 1 |
| Øllgaard, JC | 1 |
| Tofte, N | 1 |
| Tarnow, L | 1 |
| Ahluwalia, TS | 1 |
| Jorsal, A | 1 |
| Theilade, S | 1 |
| Parving, HH | 1 |
| Hansen, TW | 1 |
| Pedersen, O | 1 |
| Rossing, P | 1 |
| Rexidamu, M | 1 |
| Jin, H | 1 |
| Huang, J | 1 |
| Zhai, Q | 1 |
| Tang, Y | 1 |
| Tian, J | 1 |
| Liu, X | 1 |
| Yin, J | 1 |
| Liao, SX | 1 |
| He, Y | 1 |
| Wang, S | 1 |
| Xia, GH | 1 |
| Liu, FT | 1 |
| Zhu, JJ | 1 |
| You, C | 1 |
| Chen, Q | 1 |
| Pan, SY | 1 |
| Zhou, HW | 1 |
| Skagen, K | 1 |
| Trøseid, M | 1 |
| Ueland, T | 1 |
| Holm, S | 1 |
| Abbas, A | 1 |
| Gregersen, I | 1 |
| Kummen, M | 1 |
| Bjerkeli, V | 1 |
| Reier-Nilsen, F | 1 |
| Russell, D | 1 |
| Svardal, A | 1 |
| Karlsen, TH | 1 |
| Aukrust, P | 1 |
| Berge, RK | 1 |
| Hov, JE | 1 |
| Halvorsen, B | 1 |
| Skjelland, M | 1 |
| Obeid, S | 1 |
| Klingenberg, R | 1 |
| Mach, F | 1 |
| Räber, L | 1 |
| Windecker, S | 1 |
| Rodondi, N | 1 |
| Nanchen, D | 1 |
| Muller, O | 1 |
| Miranda, MX | 1 |
| Matter, CM | 1 |
| Wu, Y | 1 |
| Alamri, HS | 1 |
| Gogonea, V | 1 |
| Chung, YM | 1 |
| Tang, WH | 1 |
| Lüscher, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.[NCT00794885] | Phase 4 | 20,702 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
7 reviews available for trimethyloxamine and Apoplexy
| Article | Year |
|---|---|
Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.
Topics: Atherosclerosis; Humans; Ischemic Stroke; Methylamines; Risk Factors; Stroke | 2022 |
Significant correlation between the gut microbiota-derived metabolite trimethylamine-N-oxide and the risk of stroke: evidence based on 23 observational studies.
Topics: Gastrointestinal Microbiome; Humans; Methylamines; Oxides; Risk Factors; Stroke | 2023 |
Plasmatic trimethylamine N-oxide and its relation to stroke: A systematic review and dose-response meta-analysis.
Topics: Humans; Methylamines; Odds Ratio; Plasma; Risk Factors; Stroke | 2022 |
Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO.
Topics: Choline; Cognitive Dysfunction; Gastrointestinal Microbiome; Humans; Inflammation; Stroke; Thrombosi | 2024 |
The relationship between trimethylamine-N-oxide and the risk of acute ischemic stroke: A dose‒response meta-analysis.
Topics: Humans; Ischemic Stroke; Methylamines; Oxides; Stroke | 2023 |
Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis.
Topics: Case-Control Studies; Cross-Sectional Studies; Gastrointestinal Microbiome; Humans; Methylamines; Ri | 2020 |
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Dose-Response Relationship, Drug; Female; | 2017 |
4 trials available for trimethyloxamine and Apoplexy
| Article | Year |
|---|---|
[
Topics: Acupuncture Points; Acupuncture Therapy; Brain-Gut Axis; C-Reactive Protein; Humans; Interleukin-17; | 2022 |
Plasma Trimethylamine-
Topics: Aged; Atherosclerosis; Female; Humans; Ischemic Stroke; Methylamines; Oxides; Prospective Studies; R | 2023 |
Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke.
Topics: Aged; Antihypertensive Agents; Brain Ischemia; China; Choline; Cognition; Cognition Disorders; Cogni | 2021 |
Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Biomarkers; Brain Ischemia; Female; Humans; Male; Methylamines; Middle Ag | 2019 |
24 other studies available for trimethyloxamine and Apoplexy
| Article | Year |
|---|---|
Residual Risk of Trimethylamine-N-Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy.
Topics: C-Reactive Protein; Choline; Humans; Inflammation; Lipids; Methylamines; Oxides; Platelet Aggregatio | 2022 |
Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study.
Topics: Betaine; Carnitine; Case-Control Studies; Choline; Humans; Stroke | 2023 |
Related factors based on non-targeted metabolomics methods in minor ischaemic stroke.
Topics: Biomarkers; Blood Glucose; Brain Ischemia; C-Reactive Protein; Homocysteine; Humans; Hypertension; I | 2022 |
Letter to the editor about published meta-analysis of TMAO and stroke.
Topics: Gastrointestinal Microbiome; Humans; Oxides; Stroke | 2023 |
Association between plasma trimethylamine-N-oxide and cognitive impairment in patients with transient ischemic attack.
Topics: Aged; Cognitive Dysfunction; Humans; Ischemic Attack, Transient; Male; Oxides; Retrospective Studies | 2023 |
Exploratory Transcriptomic Profiling Reveals the Role of Gut Microbiota in Vascular Dementia.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Dementia, Vascular; Gastrointestinal Microbio | 2023 |
The Prognostic Biomarkers of Plasma Trimethylamine N-Oxide and Short-Chain Fatty Acids for Recanalization Therapy in Acute Ischemic Stroke.
Topics: Adult; Biomarkers; Brain Ischemia; Fatty Acids, Volatile; Humans; Ischemic Stroke; Prognosis; Prospe | 2023 |
Utility of Trimethylamine Oxide (TMAO) in Predicting Early Neurological Deterioration after Acute Ischemic Stroke.
Topics: Biomarkers; Brain Ischemia; Cohort Studies; Humans; Ischemic Stroke; Stroke; United States | 2023 |
Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke.
Topics: Aged; Betaine; Carnitine; Cerebral Small Vessel Diseases; Choline; Cross-Sectional Studies; Female; | 2023 |
Association of plasma trimethylamine-N-oxide levels with post-stroke cognitive impairment: a 1-year longitudinal study.
Topics: Aged; Aged, 80 and over; Biomarkers; Brain Ischemia; Cognitive Dysfunction; Female; Follow-Up Studie | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
The Relationship of Large-Artery Atherothrombotic Stroke with Plasma Trimethylamine N-Oxide Level and Blood Lipid-Related Indices: A Cross-Sectional Comparative Study.
Topics: Aged; Atherosclerosis; Biomarkers; Cross-Sectional Studies; Female; Humans; Lipids; Male; Methylamin | 2021 |
Gut microbes impact stroke severity via the trimethylamine N-oxide pathway.
Topics: Animals; Bacteria; Choline; Female; Gastrointestinal Microbiome; Humans; Male; Methylamines; Mice; M | 2021 |
Simultaneous determination of trimethylamine N-oxide, choline, betaine by UPLC-MS/MS in human plasma: An application in acute stroke patients.
Topics: Aged; Betaine; Choline; Chromatography, High Pressure Liquid; Female; Humans; Male; Methylamines; Pl | 2018 |
Elevated trimethylamine
Topics: Aged; Biomarkers; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Diffusion Magnetic Resonance I | 2018 |
Gut Microbiota-Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Brain Ischemia; Cardiovascular Disea | 2018 |
Serum Trimethylamine N-Oxide Concentration Is Positively Associated With First Stroke in Hypertensive Patients.
Topics: Aged; Carnitine; Case-Control Studies; China; Choline; Female; Folic Acid; Gastrointestinal Microbio | 2018 |
Trimethylamine
Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hos | 2019 |
Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Diabetic Nephropathies; Fema | 2019 |
Serum levels of Trimethylamine-N-oxide in patients with ischemic stroke.
Topics: Aged; Brain Ischemia; Female; Humans; Male; Methylamines; Middle Aged; Risk Factors; Stroke | 2019 |
Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke.
Topics: Aged; Brain Ischemia; Female; Humans; Logistic Models; Male; Methylamines; Models, Biological; Progn | 2019 |
Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Bacteria; Carotid Artery Diseases; Case-Control Stud | 2015 |
The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.
Topics: Aged; Betaine; Biomarkers; Carnitine; Carotid Stenosis; Case-Control Studies; Cause of Death; Chroma | 2016 |
Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiotonic Agents; Case-Control Studies; Female; Gastrointesti | 2017 |